Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aura Biosciences Inc (AURA)

Aura Biosciences Inc (AURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 373,260
  • Shares Outstanding, K 49,504
  • Annual Sales, $ 0 K
  • Annual Income, $ -76,410 K
  • 60-Month Beta 0.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.68
Trade AURA with:

Options Overview Details

View History
  • Implied Volatility 106.30% ( -15.65%)
  • Historical Volatility 58.54%
  • IV Percentile 70%
  • IV Rank 46.84%
  • IV High 181.80% on 11/10/23
  • IV Low 39.78% on 04/20/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 349
  • Open Int (30-Day) 283

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.44
  • Low Estimate -0.57
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.97 +8.18%
on 03/18/24
8.74 -13.73%
on 03/22/24
-0.44 (-5.51%)
since 03/12/24
3-Month
6.97 +8.18%
on 03/18/24
9.72 -22.43%
on 02/28/24
-0.83 (-9.92%)
since 01/12/24
52-Week
5.99 +25.88%
on 11/07/23
13.50 -44.15%
on 06/06/23
-1.06 (-12.33%)
since 04/12/23

Most Recent Stories

More News
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial...

AURA : 7.54 (-2.08%)
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today...

AURA : 7.54 (-2.08%)
Why Shares of Aura Biosciences Jumped This Week

The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy.

AURA : 7.54 (-2.08%)
Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that...

AURA : 7.54 (-2.08%)
Aura Biosciences Announces Pricing of Public Offering of Common Stock

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today...

AURA : 7.54 (-2.08%)
Aura Biosciences Announces Proposed Public Offering of Common Stock

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today...

AURA : 7.54 (-2.08%)
Aurora set for major expansion after SET debut, first for jewel retail biz

BANGKOK, Nov 29, 2022 - (ACN Newswire) - Aurora Design PCL (SET: AURA), one of Thailand's leaders in gold jewelry retail business, diamond jewelry and gems, is going ahead with its planned expansion after...

AURA : 7.54 (-2.08%)
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial...

AURA : 7.54 (-2.08%)
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that...

AURA : 7.54 (-2.08%)
Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that...

AURA : 7.54 (-2.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based...

See More

Key Turning Points

3rd Resistance Point 8.04
2nd Resistance Point 7.87
1st Resistance Point 7.71
Last Price 7.54
1st Support Level 7.38
2nd Support Level 7.21
3rd Support Level 7.05

See More

52-Week High 13.50
Fibonacci 61.8% 10.63
Fibonacci 50% 9.74
Fibonacci 38.2% 8.86
Last Price 7.54
52-Week Low 5.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar